prostate cancer – Medxy AI

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

By MedXY 10/31/2025

The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.

news Oncology Urology

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY 10/30/2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.

news Oncology Urology

Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study

By MedXY 10/27/2025

This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

Oncology Specialties Urology

Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial

By MedXY 10/21/2025

A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitoring.

news Oncology Radiology Urology

Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial

By MedXY 10/10/2025

The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transforming diagnostic pathways worldwide.

news Oncology Radiology Specialties Urology

PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT

By MedXY 10/04/2025

A phase 2 randomized trial demonstrates that PSMA-PET-guided intensification of salvage radiotherapy after radical prostatectomy significantly improves failure-free survival without added toxicity.

Family Medicine & Nutrition Medical News news Specialties Urology

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

By MedXY 09/19/2025

A large Harvard study finds that frequent ejaculation—about 21 times a month—is associated with a significantly reduced risk of prostate cancer among men, offering new insights into modifiable factors for prevention.

AI Clinical Updates Oncology Specialties Urology

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer

By MedXY 09/03/2025

A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessary biopsies.

Medical News Specialties Urology

Frequent Ejaculation and Prostate Cancer Risk: Insights from a Landmark Harvard Study

By MedXY 09/01/2025

A large Harvard study shows men ejaculating 21+ times monthly have a significantly reduced overall risk of prostate cancer, especially low-risk forms, across different life stages.

Oncology Specialties Urology

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

By MedXY 08/23/2025

Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.

Clinical Updates news

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management

By MedXY 08/19/2025

ArteraAI Prostate, the first FDA-approved AI-driven multimodal software, offers personalized clinical decision support for localized prostate cancer, improving treatment precision and reducing overtreatment risks.

Clinical Updates news Oncology Specialties Urology

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY 08/08/2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.

Clinical Updates Oncology Specialties Urology

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By Dr.Paul 08/07/2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates news Oncology Radiology Specialties Urology

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates news Oncology Specialties Urology

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials

By MedXY 08/02/2025

Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.